OroCAM Transmucosal Oral Spray is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. It is administered via a gentle mist onto the dog’s gums or inner cheek, where it is rapidly absorbed into the blood stream.
As the first and only veterinary non-steroidal anti-inflammatory drug (NSAID) with transmucosal oral delivery, OroCAM provides quick and reliable pain control, offering veterinary professionals a new and innovative osteoarthritis medication option that fits their clients’ needs.
The OroCAM difference includes:
- A novel transmucosal absorption that avoids first pass metabolism,1 helps eliminate roadblocks to compliance, is rapidly absorbed and offers no risk of other household pets ingesting the medication
- Effectiveness in controlling pain and inflammation2—dogs receiving OroCAM demonstrated significantly higher treatment success than those receiving placebo (n=258)2
- Dosing procedure that is well accepted by owners and dogs alike2—in more than 80 percent of dogs, administrations occurred with minimal effort in a short period of time and 85 percent of owners indicated the procedure was acceptable.
- Quick, reliable delivery2 3 given at a consistent, precise dose that doesn’t need to be given with food
Warnings, Precautions and Contraindications:
For oral use in dogs only. OroCAM should not be used in dogs with known hypersensitivity to meloxicam or other NSAIDS, dogs weighing less than 5.5 pounds (2.5 kg), or dogs younger than six months of age. It has not been evaluated for safety in breeding dogs, lactating dogs, or dogs with bleeding disorders.
This product is for dogs and should not be used in cats as it is not suitable for use in this species. Acute renal failure and death have been associated with the repeated use of meloxicam in cats.
Common adverse reactions include vomiting, diarrhea, increased liver enzyme values, and loss of appetite. In clinical studies, the signs were generally mild, transient (lasted 1-4 days during the 28-day study period), and resulted in complete recovery. There were no clinical signs related to the increased liver enzymes. Kidney or liver damage has been reported with other NSAIDs.
All dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration of any NSAID.
1. Robertson SA, Taylor PM, Sear JW. Systemic uptake of buprenorphine by cats after oral mucosal administration. Veterinary Record 2003;152:675-678.
2. Placebo-Controlled Field Efficacy Trial of Meloxicam Administered Orally Via Transmucosal Oral Mist (Promist™ Technology), in Client-Owned Dogs with Osteoarthritis, Abbott Study 09-17-MC-D-CT-MP, 2011.
3. OroCAM Spray Studies Summary, Abbott Study 11-11-MC-N-DC-MC, 2011.